Literature DB >> 33866552

Artificial Intelligence for Unstructured Healthcare Data: Application to Coding of Patient Reporting of Adverse Drug Reactions.

Louis Létinier1,2,3, Julien Jouganous3, Mehdi Benkebil4, Alicia Bel-Létoile3, Clément Goehrs3, Allison Singier1, Franck Rouby5,6, Clémence Lacroix5,6, Ghada Miremont1,2, Joëlle Micallef5,6, Francesco Salvo1,2, Antoine Pariente1,2.   

Abstract

Adverse drug reaction (ADR) reporting is a major component of drug safety monitoring; its input will, however, only be optimized if systems can manage to deal with its tremendous flow of information, based primarily on unstructured text fields. The aim of this study was to develop an automated system allowing to code ADRs from patient reports. Our system was based on a knowledge base about drugs, enriched by supervised machine learning (ML) models trained on patients reporting data. To train our models, we selected all cases of ADRs reported by patients to a French Pharmacovigilance Centre through a national web-portal between March 2017 and March 2019 (n = 2,058 reports). We tested both conventional ML models and deep-learning models. We performed an external validation using a dataset constituted of a random sample of ADRs reported to the Marseille Pharmacovigilance Centre over the same period (n = 187). Here, we show that regarding area under the curve (AUC) and F-measure, the best model to identify ADRs was gradient boosting trees (LGBM), with an AUC of 0.93 (0.92-0.94) and F-measure of 0.72 (0.68-0.75). This model was run for external validation showing an AUC of 0.91 and a F-measure of 0.58. We evaluated an artificial intelligence pipeline that was found able to learn how to identify correctly ADRs from unstructured data. This result allowed us to start a new study using more data to further improve our performance and offer a tool that is useful in practice to efficiently manage drug safety information.
© 2021 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Year:  2021        PMID: 33866552     DOI: 10.1002/cpt.2266

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

1.  Artificial Intelligence in Pharmacovigilance: An Introduction to Terms, Concepts, Applications, and Limitations.

Authors:  Jeffrey K Aronson
Journal:  Drug Saf       Date:  2022-05-17       Impact factor: 5.606

Review 2.  Intelligent Telehealth in Pharmacovigilance: A Future Perspective.

Authors:  Heba Edrees; Wenyu Song; Ania Syrowatka; Aurélien Simona; Mary G Amato; David W Bates
Journal:  Drug Saf       Date:  2022-05-17       Impact factor: 5.228

3.  Industry Perspective on Artificial Intelligence/Machine Learning in Pharmacovigilance.

Authors:  Raymond Kassekert; Neal Grabowski; Denny Lorenz; Claudia Schaffer; Dieter Kempf; Promit Roy; Oeystein Kjoersvik; Griselda Saldana; Sarah ElShal
Journal:  Drug Saf       Date:  2022-05-17       Impact factor: 5.228

4.  Black Swan Events and Intelligent Automation for Routine Safety Surveillance.

Authors:  Oeystein Kjoersvik; Andrew Bate
Journal:  Drug Saf       Date:  2022-05-17       Impact factor: 5.228

5.  Validation of Artificial Intelligence to Support the Automatic Coding of Patient Adverse Drug Reaction Reports, Using Nationwide Pharmacovigilance Data.

Authors:  Guillaume L Martin; Julien Jouganous; Romain Savidan; Axel Bellec; Clément Goehrs; Mehdi Benkebil; Ghada Miremont; Joëlle Micallef; Francesco Salvo; Antoine Pariente; Louis Létinier
Journal:  Drug Saf       Date:  2022-05-17       Impact factor: 5.228

6.  Application of artificial intelligence in a real-world research for predicting the risk of liver metastasis in T1 colorectal cancer.

Authors:  Tenghui Han; Jun Zhu; Xiaoping Chen; Rujie Chen; Yu Jiang; Shuai Wang; Dong Xu; Gang Shen; Jianyong Zheng; Chunsheng Xu
Journal:  Cancer Cell Int       Date:  2022-01-15       Impact factor: 5.722

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.